Department of Emergency Medicine, American University of Beirut, Beirut, Lebanon.
Department of Radiology, American University of Beirut, Beirut, Lebanon.
Am J Emerg Med. 2022 Sep;59:15-23. doi: 10.1016/j.ajem.2022.06.043. Epub 2022 Jun 26.
We aimed to compare the prognostic value of a quantitative CT severity score with several laboratory parameters, particularly C-reactive protein, Procalcitonin, Neutrophil to lymphocyte ratio, D-dimer, ferritin, lactate dehydrogenase, lactate, troponin and B-type Natriuretic Peptide in predicting in-hospital mortality.
This was a retrospective chart review study of COVID-19 patients who presented to the Emergency Department of a tertiary care center between February and December 2020. All patients ≥18 years old who tested positive for the COVID-19 real-time reverse transcriptase polymerase chain reaction and underwent CT imaging at presentation were included. The primary outcome was the prognostic ability of CT severity score versus biomarkers in predicting in-hospital mortality.
The AUCs were: D-dimer (AUC: 0.67 95% CI = 0.57-0.77), CT severity score (0.66, 95% CI = 0.55-0.77), LDH (0.66, 95% CI = 0.55-0.77), Pro-BNP (0.65, 95% CI = 0.55-0.76), NLR (0.64, 95% CI = 0.53-0.75) and troponin (0.64, 95% CI = 0.52-0.75). In the stepwise logistic regression, age (OR = 1.07 95% CI = 1.05-1.09), obesity (OR = 2.02 95% CI = 1.25-3.26), neutrophil/lymphocyte ratio (OR = 1.02 95% CI = 1.01-1.04), CRP (OR = 1.01 95% CI = 1.004-1.01), lactate dehydrogenase (OR = 1.003 95% CI = 1.001-1.004) and CT severity score (OR = 1.17 95% CI = 1.12-1.23) were significantly associated with in-hospital mortality.
In summary, CT severity score outperformed several biomarkers as a prognostic tool for covid related mortality. In COVID-19 patients requiring lung imaging, such as patients requiring ICU admission, patients with abnormal vital signs and those requiring mechanical ventilation, the results suggest obtaining and calculating the CT severity score to use it as a prognostic tool. If a CT was not performed, the results suggest using LDH, CRP or NLR if already done as prognostic tools in COVID-19 as these biomarkers were also found to be prognostic in COVID-19 patients.
我们旨在比较定量 CT 严重程度评分与几种实验室参数的预后价值,尤其是 C 反应蛋白、降钙素原、中性粒细胞与淋巴细胞比值、D-二聚体、铁蛋白、乳酸脱氢酶、乳酸、肌钙蛋白和 B 型利钠肽在预测住院死亡率方面的价值。
这是一项回顾性图表研究,纳入了 2020 年 2 月至 12 月期间在一家三级护理中心急诊科就诊的 COVID-19 患者。所有年龄≥18 岁、COVID-19 实时逆转录聚合酶链反应检测阳性且在就诊时接受 CT 成像的患者均被纳入研究。主要结局是 CT 严重程度评分与生物标志物在预测住院死亡率方面的预后能力。
AUC 分别为:D-二聚体(AUC:0.67,95%CI=0.57-0.77)、CT 严重程度评分(0.66,95%CI=0.55-0.77)、乳酸脱氢酶(0.66,95%CI=0.55-0.77)、Pro-BNP(0.65,95%CI=0.55-0.76)、中性粒细胞/淋巴细胞比值(0.64,95%CI=0.53-0.75)和肌钙蛋白(0.64,95%CI=0.52-0.75)。在逐步逻辑回归中,年龄(OR=1.07,95%CI=1.05-1.09)、肥胖(OR=2.02,95%CI=1.25-3.26)、中性粒细胞/淋巴细胞比值(OR=1.02,95%CI=1.01-1.04)、C 反应蛋白(OR=1.01,95%CI=1.004-1.01)、乳酸脱氢酶(OR=1.003,95%CI=1.001-1.004)和 CT 严重程度评分(OR=1.17,95%CI=1.12-1.23)与住院死亡率显著相关。
综上所述,CT 严重程度评分作为 COVID 相关死亡率的预后工具优于几种生物标志物。在需要肺部成像的 COVID-19 患者中,例如需要 ICU 入院的患者、生命体征异常的患者和需要机械通气的患者,结果提示获取和计算 CT 严重程度评分以将其作为预后工具。如果未进行 CT 检查,则提示如果已经进行了乳酸脱氢酶、C 反应蛋白或中性粒细胞/淋巴细胞比值检查,则将其作为 COVID-19 的预后工具,因为这些生物标志物在 COVID-19 患者中也被发现具有预后价值。